Diabetes
Refine Search
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
There was good news on Friday for USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) and Alkermes (Nasdaq: ALKS) as the US Food and Drug Administration finally approved their Bydureon (exenatide extended-release for injectable suspension) ' the first once-weekly treatment for type 2 diabetes. 30 January 2012
Pharmaceutical
Danish insulin giant Novo Nordisk (NVO: N) said this morning that it will establish a type 1 diabetes R&D center in Seattle, USA. The new center will combine Novo Nordisk's 'history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy,' the firm stated. 24 January 2012
Pharmaceutical
In what comes as no surprise given a negative vote by an Food and Drug Administration advisory panel last summer, Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: BMY) today announced that the FDA has issued a complete response letter (CRL) regarding the New Drug Application for the investigational compound dapagliflozin for the treatment of type 2 diabetes in adults. 19 January 2012
Pharmaceutical
Swiss drug major Novartis (NOVN: VX) says it has received regulatory approval in China from the State Food and Drug Administration (SFDA) for Lucentis (ranibizumab) to treat wet (neovascular) age-related macular degeneration (AMD), and is launching Galvus (vildagliptin), an oral treatment for patients with type 2 diabetes approved in China as an add-on to metformin, the standard of care. 18 January 2012
Pharmaceutical
LoneStar Heart, a USA-based developer of proprietary biopolymer, small molecule and cellular-based therapies to effectively treat heart failure and other cardiac conditions, says it has acquired a worldwide exclusive license from the University of Texas Southwestern Medical Center (UT Southwestern) to commercialize a new class of patented small molecules known as Isoxazoles that markedly increase insulin production in human pancreas cells no longer able to produce insulin. 18 January 2012
Pharmaceutical
Scientists in the UK may have uncovered new evidence which it is hoped could eventually help diagnose and prevent type 1 diabetes, reports the country's public broadcaster the BBC. 16 January 2012
Pharmaceutical
In a batch of final guidances released this morning by the UK's drug watchdog the Institute for Health and Clinical Excellence (NICE), the agency has recommended Swiss drug major Novartis' Tasigna (nilotinib) for the treatment of the chronic and accelerated phases of chronic myeloid leukemia (CML) that is resistant or intolerant to standard-dose imatinib. 13 January 2012
Pharmaceutical
French drug major Sanofi (Euronext: SAN) had a busy day yesterday, announcing three different collaboration agreements aimed at the discovery of drugs, including for diabetes, and companion diagnostics. 10 January 2012
Pharmaceutical
Japan's largest drugmaker, Takeda Pharmaceutical (TYO 4502) said yesterday that the European Commission has adopted the European Medicines Agency's Committee for Medical Products for Human Use (CHMP) opinion as recommended last year (The Pharma Letter October 24, 2011), which included label changes and clarification on the product indications for pioglitazone-containing medicines. 10 January 2012
Pharmaceutical
With the trend in healthcare moving toward an era of personalized medicine, there is much anticipation and hope that customized approaches to prevention and treatment based on a person's genetic make-up will result in better health outcomes. Some advances, most notably with prevention and treatment of breast and colon cancer, have been widely heralded, raising questions about the potential for personalized medicine for other common diseases, such as diabetes. 10 January 2012
Pharmaceutical
In an early benefit assessment under Germany's "Act on the Reform of the Market for Medicinal Products' (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether German family-owned drug major Boehringer Ingelheim and USA-based Eli Lilly's (NYSE: LLY) diabetes drug Trajenta (linagliptin) offers an added benefit versus the appropriate comparator therapy specified by the Federal Joint Committee (G-BA). No such added benefit can be inferred from the dossier, as the drug manufacturer deviated from the G-BA's specifications and chose a different comparator therapy, the IQWiG concluded. 10 January 2012
Generics
US generic drugmaker Mylan (Nasdaq: MYL) has confirmed that it has been sued by Takeda Pharmaceutical (TYO: 4502), Watson Pharmaceuticals (NYSE: WPI) and privately-held Andrx Labs in connection with the filing of an Abbreviated New Drug Application with the US Food and Drug Administration for pioglitazone hydrochloride and extended-release metformin HCL tablets, 15mg/1,000mg and 30mg/1,000 mg. This product is the generic version of Takeda's Actoplus Met XR, which is indicated to improve glycemic control in adults with type 2 diabetes mellitus. 9 January 2012
Pharmaceutical
Japan's largest drugmaker, Takeda Pharmaceuticals (TYO: 4502) says that it has reached a mutual agreement with US drug giant Merck & Co (NYSE: MRK), which is known as MSD outside the USA and Canada, to terminate their co-promotion agreement for Daxas (roflumilast) in certain European countries and Canada as of December 31, 2011. 3 January 2012
Pharmaceutical
Canada-based Fero Industries (OTCQB: FROI), the exclusive owner, producer and distributor of the type 2 diabetes treatment Sucanon, says it has entered into a distribution agreement with Premium Pharma. for the marketing and distribution of Sucanon in several countries in the Middle East region (Egypt, Saudi Arabia, United Arab Emirates, Bahrain, Kuwait, Qatar, Oman, Jordan, Lebanon, Iraq, Sudan and Libya). Sucanon is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers," the company notes. 23 December 2011
Pharmaceutical
Looking to expand its R&D pipeline in the face of several recent product failures and facing a 'patent cliff,' Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an option agreement with Prosidion, a fully-owned subsidiary of Japan's Astellas Pharma (TYO: 4503), granting AstraZeneca an exclusive option to acquire the Phase II clinical and preclinical assets, PSN821 and PSN 842, respectively, for the treatment of type 2 diabetes. 22 December 2011
Pharmaceutical
Danish CNS drug specialist Lundbeck (LUND: DC) revealed yesterday that it has submitted a marketing authorization application to the European Medicines Agency for Selincro (nalmefene), the company's novel opioid receptor ligand in development for alcohol dependence and the dossier has been accepted for review by EMA. 22 December 2011
Pharmaceutical
In a major disappointment for Swiss drug major Novartis (NOVN: VX), the company says that, following the seventh interim review of data from the ALTITUDE study with Rasilez/Tekturna (aliskiren), it has decided to terminate the trial in high-risk patients with diabetes and renal impairment on the recommendation of the independent Data Monitoring Committee (DMC) overseeing the trial. 21 December 2011
Biotechnology
Japanese mid-sized drugmaker Mochida Pharmaceutical (TYO: 4534) saw its shares jump 5.8% to 900 yen, after the company said it had entered into a license agreement with US drug giant Merck & Co (NYSE: MRK) relating to a portfolio of drug candidates invented by Mochida for the potential treatment for type-2 diabetes. 14 December 2011
Pharmaceutical
Dipeptidyl peptidase IV (DPP-IV) inhibitors are prescribed more commonly for the treatment of type 2 diabetes in South Korea than in China, and in earlier lines of therapy, according to surveyed physicians in these countries carried out by advisory firm Decision Resources. At the time the survey was conducted, two such oral agents were available in South Korea ' US drug giant Merck & Co's (NYSE: MRK) Januvia (sitagliptin) and Swiss major Novartis' (NOVN: VX) Galvus (vildagliptin), while only Januvia was available in China. 7 December 2011
Pharmaceutical
The European Commission has approved Swiss drug major Novartis' (NOVN: VX) Galvus (vildagliptin) (50mg once a day) for the treatment of type 2 diabetes patients with moderate or severe renal impairment. 6 December 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze